Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lymphomas
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lymphomas
    Variations in Gene Activity Can Predict the Survival of Patients With Lymphoma - (DGNews)
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Lymphomas 11/26/2008 - (DGNews)
    TopAbstracts in Lymphomas 11/12/2008 - (DGNews)
    Anaplastic large-cell lymphoma in women with breast implants - (JAMA)

    News archive

     Recent webcasts/CME - Lymphomas

    Webcasts/CME archive

     Recent cases - Lymphomas
      Primary Hepatic Lymphoma Presenting as Fulminant Hepatic Failure With Hyperferritinemia: A Case Report
      Cutaneous T-cell Lymphoma Presenting as a Ten Month History of Unilateral Facial Swelling
      Primary Multifocal Osseous Hodgkin's Lymphoma
      Primary Cerebral Lymphoma Presenting with Parkinsonism
      Primary Breast Lymphoma in the Right Breast During Treatment for Left Breast Cancer

      Cases archive
        




      my personal edition > lymphomas > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      High Dose Methotrexate Has Modest Toxicity Among CNS Lymphoma Cohort

      A DGReview of :"Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96-07"
      Journal of Clinical Oncology (JCO)

      03/26/2003
      By Harvey McConnell


      High-dose methotrexate produces modest toxicity and a radiographic response proportion of 74% among patients with primary central nervous system lymphomas. say researchers.

      These findings are reported by Dr T Batchelor and colleagues from Massachusetts General Hospital, Boston, United States, as a result of a multi-centre, phase II study of single-agent, intravenous methotrexate among patients with newly diagnosed non-AIDS-related primary CNS lymphoma in the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium.

      Twenty five patients, mean age 60 years, were given methotrexate at 8 g/mē, initially administered every two weeks. The primary end point was radiographic complete response (CR) or partial response (PR), as defined by standard radiographic criteria. Secondary endpoints were drug-related toxicity and survival.

      The patients all had median Karnofsky Performance Score of 80. Three of 14 patients who underwent lumbar puncture had malignant cells on CSF cytopathology, and 5 of the 25 patients had ocular involvement. Two patients could not be evaluated for the primary end point because one did not have any measurable disease, and the second died before radiologic imaging.

      All patients either completed the treatment program, or progressed with treatment. Among 23 of the patients, there was a complete response among 12 (52%), a partial response among 5 (22%), 1 (4%) had disease stability, and 5 (22%) had progression while receiving therapy.

      Seven of the patients eventually died from progression of their tumour, while 2 died of other causes. Median progression-free survival was 12.8 months, and the median overall survival for the entire group had not been reached at 22.8+ months.

      The clinicians found following 287 cycles of chemotherapy, that toxicity was modest following the methotrexate regimen, and with no grade 3 or 4 toxicity in 13 of 25 patients. There was a grade 3 toxicity among eight of 25 patients, and a grade 4 toxicity among four of 25 patients.
      J Clin Oncol 2003 Mar;21:6:1044-9. "Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96-07"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send